Use of risk scores to identify lower and higher risk subsets among COMPASS‐eligible patients with chronic coronary syndromes. Insights from the CLARIFY registry

BACKGROUND: The COMPASS trial showed a reduction of ischemic events with low‐dose rivaroxaban and aspirin in chronic coronary syndromes (CCS) compared with aspirin alone, at the expense of increased bleeding. HYPOTHESIS: The CHA(2)DS(2)VaSc Score, REACH Recurrent Ischemic (RIS), and REACH Bleeding R...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Clin Cardiol
Autors principals: Darmon, Arthur, Ducrocq, Gregory, Jasilek, Adam, Feldman, Laurent, Sorbets, Emmanuel, Ferrari, Roberto, Ford, Ian, Tardif, Jean‐Claude, Tendera, Michal, Fox, Kim M., Steg, Philippe Gabriel
Format: Artigo
Idioma:Inglês
Publicat: Wiley Periodicals, Inc. 2020
Matèries:
Clinical Investigations
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7803362/
https://ncbi.nlm.nih.gov/pubmed/33274779
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/clc.23505
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars